Astera Labs Q3 beat and Q4 guide signal Scorpio ramp accelerating revenue per accelerator

What happened

Astera Labs reported Q3 2026 revenue of $585M, exceeding the prior guided range of $540-560M, driven by the Scorpio X-Series switch ramp and higher content per accelerator. The company guided Q4 2026 revenue midpoint to $740M, implying roughly 26% sequential growth and reflecting management's confidence in continued demand. Gross margin is expected to remain around 72%, consistent with the hardware-heavy Scorpio mix that compresses profitability relative to earlier quarters. The article highlights Scorpio X delivering over $1,000 content per XPU and points to new opportunities in optical, custom silicon, and rack-level solutions, but it does not address customer concentration or diversification. While the operational update is positive, the stock still trades at extreme valuations (166x earnings, 275x EV/EBITDA) and concentration risk remains high with four customers representing 13-29% of Q2 revenue.

Implication

The Q3 beat and strong Q4 guide validate the Scorpio-driven growth thesis and may justify a higher near-term trading range. However, gross margin staying at ~72% confirms that incremental revenue carries lower profitability, limiting operating leverage. Customer concentration remains the primary structural risk; until the top two customers' share declines meaningfully, the stock remains vulnerable to single-program shifts. The article's emphasis on revenue per accelerator is positive but glosses over whether this is coming from existing customers or new ones. Given the stretched valuation, investors should wait for either a pullback toward the $300 attractive entry or evidence of broader customer adoption and margin stabilization above 73% before adding.

Thesis delta

The prior Wait thesis hinged on whether Q3 revenue would exceed $560M and gross margin stay above 72.5%; actual Q3 revenue of $585M beat the upper bound but margin came in at ~72%, slightly below that threshold. The sharp Q4 guide to $740M suggests the Scorpio ramp is accelerating faster than modeled, but it is accompanied by continued margin pressure and no evidence of customer diversification. Consequently, the risk/reward improves on the revenue side but not on the quality of earnings or concentration, so the rating remains Wait but with a narrower window to prove breadth before the stock deserves a higher valuation.